Top Dividend Stocks Rebounding: Apple and Eli Lilly

Apple (AAPL)

Apple's rebound is attributed to efforts to mitigate tariff impacts and the anticipation of a strong iPhone 17 cycle. The company's Q3 2025 results showed a 10% year-over-year revenue increase to $94 billion, with earnings per share rising 12% to $1.57. Apple's services segment, with over 2 billion active devices and 1 billion paid subscriptions, is a key growth driver.

For dividend seekers, Apple's forward yield is around 0.4%. However, its substantial free cash flow and a conservative payout ratio of 16% indicate potential for future dividend increases. Over the past decade, Apple has increased its dividends by 100%.

Eli Lilly (LLY)

Eli Lilly's stock rebounded after positive data from a Phase 3 study of orforglipron in overweight or obese diabetic patients. The drug demonstrated significant weight loss and A1C reductions, positioning it for regulatory submissions. Eli Lilly is also progressing with retatrutide, which has shown promising weight loss results in Phase 2 studies.

Eli Lilly's dividend has increased by 200% in the past decade. With a payout ratio of about 44% and a forward yield of 0.8%, the company's strong business and commitment to dividend growth make it an attractive option.

Sources

What is driving Apple's rebound?

Anticipation of a strong iPhone 17 cycle and growth in its services segment.

What is contributing to Eli Lilly's resurgence?

Positive data from Phase 3 studies of orforglipron and progress with retatrutide.

Apple and Eli Lilly are rebounding dividend stocks with potential upside. Apple benefits from a strong ecosystem and potential iPhone cycle, while Eli Lilly is driven by promising drug approvals and weight loss market dominance. Both offer growing dividends, making them attractive for long-term investors.

Do you think these stocks will continue to rebound? Share your thoughts in the comments!

Share this article with others who need to stay ahead of this trend!